A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C Genotype 1 Who Have Failed Prior HCV Protease Inhibitor Treatment
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 10 Jun 2016
At a glance
- Drugs Mericitabine (Primary) ; Danoprevir; Peginterferon alfa-2a; Ribavirin; Ritonavir
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Roche
- 21 Jul 2014 Planned End Date changed from 1 Jul 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
- 21 Jul 2014 Planned primary completion date changed from 1 Jul 2014 to 1 Mar 2014 as reported by ClinicalTrials.gov record.
- 05 Sep 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.